Bleakley Financial Group LLC Purchases 27,674 Shares of Sanofi $SNY

Bleakley Financial Group LLC lifted its position in shares of Sanofi (NASDAQ:SNY) by 21.4% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 157,264 shares of the company’s stock after purchasing an additional 27,674 shares during the quarter. Bleakley Financial Group LLC’s holdings in Sanofi were worth $7,577,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Brighton Jones LLC lifted its holdings in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares during the period. AQR Capital Management LLC grew its holdings in Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after acquiring an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Sanofi by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after acquiring an additional 752 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after acquiring an additional 347 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Sanofi by 36.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after purchasing an additional 875 shares during the period. Institutional investors own 14.03% of the company’s stock.

Sanofi Stock Down 1.9%

SNY stock opened at $43.18 on Wednesday. The stock’s 50 day simple moving average is $43.30 and its 200 day simple moving average is $45.59. The company has a market cap of $104.69 billion, a P/E ratio of 12.06, a price-to-earnings-growth ratio of 1.12 and a beta of 0.34. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SNY shares. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Morgan Stanley set a $49.00 price target on Sanofi in a research note on Wednesday, July 8th. Citigroup restated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Argus raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Finally, BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $49.50.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.